Status: Recruiting
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?
Participants needed: 20
Trial details
Phase: Phase 2, Phase 3Age: 15-90Biological sex: AllType: InterventionalSponsor: Hospital Regional de Alta Especialidad del BajioUpdated: Mar 12, 2025Locations: 1
Eligibility criteria
Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk. [+7]
Voluntary withdrawal from the study. [+2]